These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36565704)

  • 21. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
    Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
    Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
    Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.
    Wolfson LJ; Walker A; Hettle R; Lu X; Kambili C; Murungi A; Knerer G
    PLoS One; 2015; 10(3):e0120763. PubMed ID: 25794045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost of digital technologies and family-observed DOT for a shorter MDR-TB regimen: a modelling study in Ethiopia, India and Uganda.
    Rosu L; Madan J; Bronson G; Nidoi J; Tefera MG; Malaisamy M; Squire BS; Worrall E
    BMC Health Serv Res; 2023 Nov; 23(1):1275. PubMed ID: 37980524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial.
    Madan JJ; Rosu L; Tefera MG; van Rensburg C; Evans D; Langley I; Tomeny EM; Nunn A; Phillips PP; Rusen ID; Squire SB;
    Bull World Health Organ; 2020 May; 98(5):306-314. PubMed ID: 32514196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
    Schnippel K; Ndjeka N; Maartens G; Meintjes G; Master I; Ismail N; Hughes J; Ferreira H; Padanilam X; Romero R; Te Riele J; Conradie F
    Lancet Respir Med; 2018 Sep; 6(9):699-706. PubMed ID: 30001994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania.
    Mbelele PM; Mpolya EA; Sauli E; Mtafya B; Ntinginya NE; Addo KK; Kreppel K; Mfinanga S; Phillips PPJ; Gillespie SH; Heysell SK; Sabiiti W; Mpagama SG
    J Clin Microbiol; 2021 Mar; 59(4):. PubMed ID: 33536294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
    Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
    Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation.
    Souleymane MB; Decroo T; Soumana A; Maman Lawan I; Gagara-Issoufou A; Halidou-Moussa S; Ortuño-Gutiérrez N; Adehossi E; Mamadou S; Van Deun A; Piubello A
    Trials; 2022 Dec; 23(1):1011. PubMed ID: 36514153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
    Van Deun A; Decroo T; Tahseen S; Trébucq A; Schwoebel V; Ortuno-Gutierrez N; de Jong BC; Rieder HL; Piubello A; Chiang CY
    Int J Antimicrob Agents; 2020 Jan; 55(1):105822. PubMed ID: 31626907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis.
    Masuku SD; Berhanu R; Van Rensburg C; Ndjeka N; Rosen S; Long L; Evans D; Nichols BE
    Int J Tuberc Lung Dis; 2020 Apr; 24(4):376-382. PubMed ID: 32317060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens.
    Park HY; Kwon JW; Kim HL; Kwon SH; Nam JH; Min S; Oh IS; Bea S; Choi SH
    J Korean Med Sci; 2023 May; 38(21):e167. PubMed ID: 37270920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of rifampicin-resistant tuberculosis in conflict-affected areas: The case of Iraq.
    Tesfahun HM; Al-Salihi L; Abdulkareem Al-Ani N; Mankhi AA; Mohammed A; Lim CAE; Al-Hilfi RA; Jouego CG; Decroo T; Moussally K; Ferlazzo G; Isaakidis P
    PLoS One; 2024; 19(1):e0296952. PubMed ID: 38241233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study.
    Ryckman TS; McQuaid CF; Cohen T; Menzies NA; Kendall EA
    Lancet Glob Health; 2024 Oct; 12(10):e1629-e1637. PubMed ID: 39159654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings.
    Khan PY; Franke MF; Hewison C; Seung KJ; Huerga H; Atwood S; Ahmed S; Khan M; Sultana T; Manzur-Ul-Alam M; Vo LNQ; Lecca L; Yae K; Kozhabekov S; Tamirat M; Gelin A; Vilbrun SC; Kikvidze M; Faqirzai J; Kadyrov A; Skrahina A; Mesic A; Avagyan N; Bastard M; Rich ML; Khan U; Mitnick CD
    Eur Respir J; 2022 Jan; 59(1):. PubMed ID: 34140298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
    Mok J; Lee M; Kim DK; Kim JS; Jhun BW; Jo KW; Jeon D; Lee T; Lee JY; Park JS; Lee SH; Kang YA; Lee JK; Kwak N; Ahn JH; Shim TS; Kim SY; Kim S; Kim K; Seok KH; Yoon S; Kim YR; Kim J; Yim D; Hahn S; Cho SN; Yim JJ;
    Lancet; 2022 Oct; 400(10362):1522-1530. PubMed ID: 36522208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort Study.
    Morgan H; Ndjeka N; Hasan T; Gegia M; Mirzayev F; Nguyen LN; Schumacher S; Schlub TE; Naidoo K; Fox GJ
    Clin Infect Dis; 2024 Jun; 78(6):1698-1706. PubMed ID: 38525535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.